Strategic capital and acquisitions are driving rapid progress across multiple therapeutic and diagnostic areas. With funding flowing into neuromodulation, AI diagnostics, surgical robotics, and remote monitoring, the industry is turning ambitious ideas into real-world solutions. Get the full details below.
Rocamed and Delmont Imaging forging a new Uro-Gyn era
Тhe integration brings together Rocamed’s global urology and laparoscopy portfolio with Delmont Imaging’s CE-certified gynecological endoscopy systems, including hysteroscopes, resectoscopes, and outpatient “see-and-treat” technologies.
The acquisition expands Rocamed’s reach across minimally invasive urology and gynecology, leveraging Delmont’s strong presence in gynecological imaging and outpatient care. Both companies are expected to benefit from shared manufacturing, regulatory, and global distribution strengths.
CEO of Rocamed Olivier Jaigu
President of Delmont Imaging Pierre Montillot
Last week’s tracker: Kestra, Akura & more
Saluda Medical raises $150M in Australian IPO to support neuromod tech
Saluda Medical announced that it raised $150 million through an initial public offering on the Australian Securities Exchange (ASX). The raised A$230.8 million through its Australian IPO, beginning trading last week under the “SLD” ticker.
Existing securityholders involved in the IPO include Wellington Management, Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., TPG Life Sciences Innovations, Redmile Group, LLC, and others. The company plans to use the funds to expand its sales team, marketing and commercial support and product development.
President and CEO Barry Regan
WELLSTAR Technologies closes $62M financing to support its pre-spinout growth strategy
The company has completed its previously announced Series B Preferred Share financing, raising aggregate gross proceeds of approximately $62 million. Under the Series B Financing, WELLSTAR issued an aggregate of 41,352,598 Series B Preferred Shares at an offering price of $1.50 per Series B Share.
The Series B Financing was supported by three of Canada’s most prominent fund investors, Mawer Investment Management Ltd., Edgepoint Wealth Management Inc. and PICTON Investments.
CEO Amir Javidan
Cardinal Capital Group invest $35m in Cathedral Eye Clinic
Private equity company Cardinal Capital Group has invested $35m into Cathedral Eye Clinic, which operates specialist eye-surgery clinics in Belfast and Birmingham. The investment will allow the company to expand its clinics in Ireland, Northern Ireland and England.
It now plans to build a new ophthalmology clinic in Belfast, doubling the surgery capacity of its existing clinic there. The group is also planning a new ophthalmology unit for Dublin and a new clinic in England.
Founder Johnny Moore
Inito raises $29M in Series B funding
The startup raised $29 million in Series B funding to scale its at-home health diagnostics platform and use AI-designed antibodies to unlock new kinds of at-home tests.
The funding round was led by Bertelsmann India Investments and Fireside Ventures. The investment brings Inito’s total funding to around $45 million.
Co-Founder and CEO Aayush Rai
Subsense expands financing to $27M for non-surgical brain-computer interfaces
The company added $10 million in new capital following positive early breakthroughs, bringing total funding to $27 million.
The investment from Golden Falcon Capital will accelerate research and development in nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design, and hardware miniaturization.
Co-Founder and CEO Tetiana Aleksandrova
Kitea Health closes $13M raise
Kitea Health has closed an over-subscribed funding round at $13 million, co-founder and chief executive Professor Simon Malpas says.
The firm is also on track to begin human trials in the US, following the completion of its first round of human trials, conducted at Auckland Hospital
Co-Founder and CEO Simon Malpas
Catalpa secures $11m for its first healthtech fund
Catalpa Ventures has completed a first closing of $11m for its Catalpa Health Fund I, a Luxembourg-based vehicle dedicated to early-stage European healthtech startups.
The target size is €30m by 2027, with plans to invest in 15 to 20 companies in pre-seed and seed stages. The fund has already committed its first ticket to Noah Labs.
Partner Thomas Goergen
Mirai Medical has been awarded $8M under the DTIF for PIONEER
Mirai Medical has been awarded $8M under the Disruptive Technologies Innovation Fund Call 7 for PIONEER – Pathology and Immuno-Oncology with Next-Generation Screening and Electroporation for Enhanced Response.
PIONEER is delivered in collaboration with Trinity College Dublin, University of Galway, University College Dublin, Eurofins and Deciphex with clinical studies being completed at St James’s Hospital Dublin, bringing together national expertise from digital pathology, biomarkers, and translational oncology.
CEO Declan Soden
Virtonomy closes $5.8M Series A round
The round was led by Companisto with a renewed and strengthened commitment from Bayern Kapital. The new capital will drive the next phase of the company’s growth.
Virtonomy aims to scale its platform further internationally, advancing regulatory validation to integrate virtual trials into real-world approval pathways, and expanding its global footprint and team.
CEO Simon J. Sonntag
